Lv21
130 积分 2025-02-11 加入
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
1小时前
待确认
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? – Authors' reply
1个月前
已完结
Ianalumab plus Eltrombopag in Immune Thrombocytopenia
1个月前
已关闭
Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension
2个月前
已完结
A phase 3, randomized, double‐blind, active‐controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP
2个月前
已完结
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study
2个月前
已完结
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)
2个月前
已完结
Corrections to “Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines”
2个月前
已完结
Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study
3个月前
已完结
Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?
3个月前
已完结
皖公网安备34019202002308
